Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AstraZeneca Board Rejects Pfizer Proposal

Published: Friday, May 02, 2014
Last Updated: Friday, May 02, 2014
Bookmark and Share
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.

The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged. Accordingly, the Board has rejected the Proposal.

Leif Johansson, Chairman of AstraZeneca, said: “AstraZeneca continues to invest significantly in research, development and manufacturing in the U.K., Sweden and the U.S. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders. Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery. As such, the Board has no hesitation in rejecting the Proposal.”

AstraZeneca have advised shareholders to take no action. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca and MAP Collaborate for Development and Commercialization of Unit Dose Budesonide
Unit Dose Budesonide is being developed as a potential treatment for pediatric asthma and is currently in Phase III clinical development.
Monday, December 22, 2008
AstraZeneca Announces Partnership with Singapore Institutions to Develop Anti-Cancer Compounds
The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients.
Tuesday, August 19, 2008
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
Wednesday, July 02, 2008
AstraZeneca Enhances Clinical Research Capabilities in China with First Clinical Pharmacology Unit
The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients.
Wednesday, September 05, 2007
Integration of the Hamilton Microlab Star within HtL at AstraZeneca R&D Charnwood
The use of the flexible and modular Microlab® Star enables AstraZeneca to use one instrument for diverse applications ranging from compound dilution to assay construction.
Wednesday, June 06, 2007
AstraZeneca Inaugurates Global Process R&D lab in Bangalore
According to AstraZenec, the facility will strengthen the global PR&D programmes as well as provide support to the existing Drug Discovery programme at Bangalore.
Thursday, March 22, 2007
Scientific News
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Pharmacy on Demand
New, portable system can be configured to produce different drugs.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Countless New, Cleaner Uses of Methane
Chemists have demonstrated the potential to use methane as a versatile chemical building block with which to make more complex molecules.
New Way to Control Chemical Reactions
Scientists have harnessed static electricity to control chemical reactions for the first time, in a breakthrough that could bring cleaner industry and cheaper nanotechnology.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!